Trial Profile
A Retrospective, Real-World Evidence Study to Compare Treatment Outcomes of Promacta (Eltrombopag) with Other Second-Line Therapies in Immune Thrombocytopenia (ITP) Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Dec 2018
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary) ; Rituximab; Romiplostim
- Indications Idiopathic thrombocytopenic purpura; Thrombocytopenia
- Focus Adverse reactions; Therapeutic Use
- 13 Dec 2018 New trial record
- 04 Dec 2018 Results (n=2047) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 02 Dec 2018 Results comparing outcomes of eltrombopag with other second-line therapies in real world ITP patients, presented in a Novartis media release.